The noncompetitive NMDA receptor blocker ketamine provides significant improvement to patients suffering from depression but its mechanistic pathways are not fully understood.The endogenous opioid system is known to be dysregulated in patients with depression.Ketamine is known to interact with the opioid system either directly or indirectly through the release of endogenous opioids.In this...